Global point of care (POC) drugs of abuse testing market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account from USD 1625.14 million in 2020 to USD 2311.12 million by 2028 growing at a CAGR of 4.50% in the above-mentioned forecast period.
Drugs of abuse is basically the illegal prescribed substances consumed for a non-medical purpose. The point of care (POC) drugs of abuse testing deals with the detection of illegal substances in the urine, blood, saliva, hair or sweat which is done at a specified testing location rather than the sample being sent to a laboratory.
The high prevalence of drug abuse in individuals especially teenagers and the usage of point of care drugs of abuse testing in sports are primarily driving the growth of the point of care (POC) drugs of abuse testing market. Additionally, the known advantages of point of care drugs of abuse testing such as reduced potential for contamination or deterioration, fewer requirements to aliquot specimens or store samples and portability are the reason for high adoption and usage of point of care (POC) drugs of abuse testing. On the other hand, the point of care testing devices may not be as reliable and accurate as compared to the laboratory-based testing’s due to high probability of falser positive or negative results which might restrain the overall growth of the market. The increasing number of regulatory approvals for and the rising usage of home-based point of care devices is estimated to generate new opportunities within the forecast period.
Point of care (POC) Drugs of Abuse Testing Market Country Level Analysis
Point of care (POC) drugs of abuse testing market is analysed and market size insights and trends are provided by drugs type, product, sample type and end-user as referenced above.
The countries covered in the point of care (POC) drugs of abuse testing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Healthcare Infrastructure growth Installed base and New Technology Penetration
Point of care (POC) drugs of abuse testing market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for point of care (POC) drugs of abuse testing market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the point of care (POC) drugs of abuse testing market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Point of care (POC) Drugs of Abuse Testing Market Share Analysis
The major players covered in the point of care (POC) drugs of abuse testing market report are uest Diagnostics Incorporated, Abbott, AdvaCare Pharma, Cliawaived Inc., DRUGSCAN, Millennium Health, BD, Agilent Technologies Inc., Danaher, Bio-Rad Laboratories Inc., Cellavision, JOYSBIO (Tianjin) Biotechnology Co., Ltd, NIHON KOHDEN CORPORATION, Ortho Clinical Diagnostics, F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, Sysmex Corporation, Merck KGaA, Cardinal Health, Takara Bio Inc., bioMérieux SA, Enzo Life Sciences Inc., among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.